Abramson Cancer Center Support Grant

艾布拉姆森癌症中心支持补助金

基本信息

批准号：
10514665
负责人：
ROBERT H VONDERHEIDE
金额：
$ 4.51万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-01-15 至 2025-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10514665
关键词：
Abramson Cancer Center at the University of Pennsylvania Address Adult Area Automobile Driving Basic Science Beverages Black race Breast Cancer Burden Cancer Center Cancer Center Support Grant Cancer Control Cancer Patient Capital Caring Catchment Area Cause of Death Cells Cellular biology Child Clinical Clinical Data Clinical Investigator Clinical Protocols Clinical Research Clinical Sciences Clinical Trials Collaborations Colorectal Community Outreach Comprehensive Cancer Center Country County DNA Damage Delaware Development Diagnosis Disease Early Diagnosis Ecosystem Enrollment Epigenetic Process Face Fostering Funding Genetic Geography Health Policy Health Services Research Health behavior Hospitals Human Papilloma Virus Vaccination Immunology Immunotherapy Incidence Intervention Trial Journals Laboratories Laboratory Research Leadership Lung Lymphoma Malignant Childhood Neoplasm Malignant Neoplasms Manuscripts Medicine Mission Modernization Monitor Nature New Jersey Oncogenes Paper Patients Pediatric Hospitals Pennsylvania Philadelphia Population Population Research Population Sciences Prevention Prostate Protocols documentation Proton Radiation Publications Publishing Recording of previous events Research Research Personnel Resource Sharing Resources Rest Risk Risk Assessment Risk Factors Science Scientist Smoking System T-Lymphocyte Training and Education Translating Translational Research Translations Underrepresented Populations United States United States National Institutes of Health Universities Vision anticancer research base behavioral economics brca gene cancer care cancer education cancer risk cancer surgery chimeric antigen receptor T cells clinical investigation clinical practice community engagement data management environmental toxicology ethnic diversity gene therapy health care delivery improved innovation melanoma member microbiome molecular imaging novel strategies novel therapeutic intervention outreach patient oriented population based prevent programs proton therapy public health relevance radiomics response smoking cessation survivorship targeted treatment tobacco control translational scientist treatment trial tumor metabolism tumor microenvironment

项目摘要

PROJECT SUMMARY – Abramson Cancer Center The Abramson Cancer Center (ACC) at the University of Pennsylvania is one of the oldest NCI-Designated Comprehensive Cancer Centers. The ACC serves an ethnically and economically diverse catchment area – 12 contiguous counties in Pennsylvania, New Jersey, and Delaware, with approximately 7 million residents. Residents in our catchment area face significantly higher rates of cancer incidence than the rest of the country. Through integrated, dynamic, and high-impact Research Programs pursuing basic, clinical, and population- based research, the ACC fosters pioneering scientific discoveries and facilitates the translation of these discoveries into clinical practice, transforming paradigms of patient-centered cancer care and cancer control. ACC provides extraordinary cancer care at three Penn Medicine adult hospitals and Children's Hospital of Philadelphia. The ACC is further enhanced by being part of the powerful academic ecosystem of the University of Pennsylvania. The ACC mission is to reduce the burden of cancer throughout our catchment area, the nation, and the world through uniquely integrated, productive, and comprehensive research efforts. Our vision is to exemplify an exceptional science-driven, patient-focused comprehensive cancer center with deep and lasting impact. The ACC has 324 members, nine Research Programs, nine Shared Resources, and robust teams for Community Outreach and Engagement, Clinical Protocol and Data Management, Protocol Review and Monitoring Systems, Cancer Research Training and Education, and Administration. In the current funding period, ACC members published 4,052 manuscripts and enrolled more than 22,000 subjects on interventional trials and more than 37,000 subjects on non-interventional trials. ACC members hold $170.1M in annual direct funds, of which $103.2M comes from the NIH and $59.2M from the NCI. ACC members hold 267 R01- equivalents. Notable strengths of the ACC include extraordinary intellectual capital, a uniquely collaborative culture that drives translational research, a balanced and strong research portfolio, deep commitment to our catchment area, and a modern and expanding cancer clinical enterprise for the care of adults and children. Chief accomplishments in the current funding period include transformative science in immunology, cell biology, germline genetics, and epigenetics; clinical trials with impact ranging from bench-to-beside discovery to multiple FDA approvals, including development, translation, and FDA approval of CAR T cells as the first cancer gene therapy; novel approaches in proton radiation and molecular imaging; nation-leading efforts in smoking cessation and HPV vaccination; doubling of Black subjects' participation in clinical trials; and leadership driving new health policy around smoking and sugary beverages. By leveraging new Institutional, philanthropic, and other resources, the ACC continues to innovate to reduce the burden of cancer in our catchment area and beyond, relentlessly working in a comprehensive and rigorous fashion to improve the lives of cancer patients and those at risk.

项目摘要 - 艾布拉姆森癌症中心宾夕法尼亚大学的艾布拉姆森癌症中心（ACC）是最古老的NCI指定的之一综合癌症中心。 ACC在种族和经济上为各种流域提供服务 - 12 宾夕法尼亚州，新泽西州和特拉华州的连续县，约有700万居民。我们集水区的居民面临的癌症事件发生率明显高于该国其他地区。通过综合，动态和高影响力的研究计划，追求基本，临床和人群 - 基于研究，ACC培养了开创性的科学发现，并促进了这些发现的翻译发现临床实践，改变了以患者为中心的癌症护理和癌症控制的范例。 ACC在三家宾夕法尼亚州成人医院和儿童医院提供非凡的癌症护理费城。成为大学强大的学术生态系统的一部分，进一步增强了ACC 宾夕法尼亚州。 ACC的任务是减少整个流域的癌症的燃烧，国家和世界通过独特的整合，生产性和全面的研究工作。我们的愿景是举例说明一个具有特殊科学驱动的，以患者为中心的综合癌症中心，持久的影响。 ACC有324名成员，九个研究计划，9个共享资源和强大的资源社区宣传和参与，临床协议和数据管理的团队，协议审查以及监测系统，癌症研究培训和教育以及管理。在当前的资金中 ACC成员发表了4,052份手稿，并入学了22,000多名介入的受试者在非间接试验中的试验和超过37,000名受试者。 ACC成员持有1.701亿美元的年度直接资金，其中1.032亿美元来自NIH，NCI为5920万美元。 ACC成员持有267 R01- 等效物。 ACC的显着优势包括非凡的智力资本，这是一个独特的协作驱动转化研究的文化，一种平衡，强大的研究组合，对我们的深刻承诺集水区，以及一个现代而扩大的癌症临床企业，用于成人和儿童的护理。当前资金期间的主要成就包括免疫学方面的变革科学，细胞生物学，种系遗传学和表观遗传学；临床试验的影响范围从板凳到贝赛德发现多次FDA批准，包括开发，翻译和FDA批准CAR T细胞作为第一个癌基因治疗；质子辐射和分子成像的新方法；国家领导的努力戒烟和HPV疫苗接种；黑人受试者参与临床试验的加倍；和领导力围绕吸烟和含糖卧室推动新的健康政策。通过利用新机构，慈善和其他资源，ACC继续进行创新，以减少我们的癌症燃烧集水区及以后，以全面而严格的方式远程工作，以改善生活癌症患者和有危险的患者。